Viking Therapeutics, Inc. Debt Securities, Available-for-sale
Viking Therapeutics, Inc. (VKTX) had Debt Securities, Available-for-sale of $375.91 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-07-29
- 2026-06-30: Debt Securities, Available-for-sale $375.91M.
- 2026-03-31: Debt Securities, Available-for-sale $484.85M.
- 2025-12-31: Debt Securities, Available-for-sale $539.93M.
- 2025-09-30: Debt Securities, Available-for-sale $614.19M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $375.91M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $484.85M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $539.93M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $614.19M 10-Q · filed 2025-10-23 |
| 2025-06-30 | $773.84M 10-Q · filed 2025-07-23 |
| 2025-03-31 | $813.92M 10-Q · filed 2025-04-24 |
| 2024-12-31 | $875.94M 10-K · filed 2026-02-11 |
| 2024-09-30 | $880.09M 10-Q · filed 2024-10-23 |
| 2024-06-30 | $898.35M 10-Q · filed 2024-07-24 |
| 2024-03-31 | $767.40M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $306.56M 10-K · filed 2025-02-26 |
| 2023-09-30 | $339.06M 10-Q · filed 2023-10-25 |
| 2023-06-30 | $323.40M 10-Q · filed 2023-07-26 |
| 2023-03-31 | $117.30M 10-Q · filed 2023-04-26 |
| 2022-12-31 | $118.85M 10-K · filed 2024-02-07 |
| 2021-12-31 | $175.73M 10-K · filed 2023-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |